Pharmacoeconomic analysis of treatment strategies for osteoporosis in postmenopausal women: A systematic review;Análise farmacoeconômica das estratégias de tratamento da osteoporose em mulheres na pós-menopausa: Uma revisão sistemática

Revista Brasileira de Reumatologia

Volumn 52, Issue 6, 2012, Pages 924-937

  Brandão, Cristina Mariano Ruas ^a,b,c   Machado, Gustavo Pinto da Matta ^a,b   Acurcio, Francisco de Assis ^b,d  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UFMG   (Brazil)

^c FUNDAÇÃO HOSPITALAR DO ESTADO DE MINAS GERAIS   (Brazil)

^d UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; DENOSUMAB; ESTROGEN; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

BRAZIL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; FEMUR FRACTURE; HIP FRACTURE; HORMONAL THERAPY; HUMAN; HUMERUS FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY ADJUSTED LIFE YEAR; REVIEW; SPINE FRACTURE; SYSTEMATIC REVIEW; WRIST FRACTURE; ECONOMICS; FEMALE; PHARMACOECONOMICS;

BRAZIL; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 84873036496     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0482-50042012000600010     Document Type: Review

References (59)

1. WHO (World Health Organization) Scientific Group on the Prevention and Management of Osteoporosis: Prevention and Management of Osteoporosis. Technical Report Series 921. Geneva; 2003.
2. Instituto Brasileiro de Geografia e Estatística (IBGE). População. [Acessed on 29 sep 2010]. Available from: http://www.ibge.gov.br/home/mapa_site/mapa_site.php#populacao.
3. Clark P, Cons-Molina F, Deleze M, Ragi S, Haddock L, Zanchetta JR et al. The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American Vertebral Osteoporosis Study (LAVOS). Osteoporos Int 2009; 20(2):275-82.
4. Pinheiro MM, Ciconelli RM, Jacques NO, Genaro PS, Martini LA, Ferraz MB. The burden of osteoporosis in Brazil: regional data from fractures in adult men and women - The Brazilian Osteoporosis Study (BRAZOS). Rev Bras Reumatol 2010; 50(2):113-20.
5. Lopes JB, Figueiredo CP, Caparbo VF, Takayama L, Menezes PR, Scazufca M et al. Osteoporotic fractures in the Brazilian communitydwelling elderly: prevalence and risk factors. J Clin Densitom 2011; 14(3):359-66.
6. Genant HK, Li J, Wu CY, Shepherd JA. Vertebral fractures in osteoporosis: a new method for clinical assessment. J Clin Densitom 2000; 3(3):281-90.
7. Silveira VA, Medeiros MM, Coelho-Filho JM, Mota RS, Noleto JCS, Costa FS et al. Incidência de fratura do quadril em área urbana do Nordeste brasileiro. Cad Saúde Pública 2005; 21(3):907-12.
8. Kowalski SC, Sjenzfeld VL, Ferraz MB. Resource utilization in postmenopausal osteoporosis without incident fractures. J Rheumatol 2004; 31(5):938-42.
9. Brandão CMR. Avaliação econômica dos medicamentos destinados ao tratamento da osteoporose no programa de medicamentos excepcionais do Ministério da Saúde [manuscrito]. Belo Horizonte: UFMG; 2008.
10. Bracco OL, Fortes EM, Raffaelli MP, Araújo DV, Santili C, Castro ML. Custo hospitalar para tratamento da fratura aguda do fêmur por osteoporose em dois hospitais-escola conveniados ao Sistema Único de Saúde. J Bras Econ Saude 2009; 1(1):3-10.
11. Araújo DV, Oliveira JH, Bracco OL. Custo da fratura osteoporótica de fêmur no sistema suplementar de saúde brasileiro. Arq Bras Endocrinol Metababol 2005; 49(6):897-901.
12. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd edition, Oxford University Press; 2005.
13. Brasil. Ministério da Saúde. Avaliação econômica em Saúde: desafios para gestão no Sistema Único de Saúde. Brasília: Editora do Ministério da Saúde, 2008.
14. Brasil. Ministério da Saúde. Avaliação de tecnologias em Saúde: ferramentas para a gestão do SUS. Brasília: Editora do Ministério da Saúde, 2009. P.110 (Série A. Normas e Manuais técnicos).
15. WHO (World Health Organization). CHOosing Interventions that are Cost Effective (WHO-CHOICE). Cost-effectiveness thresholds. Available from: http://www.who.int/choice/costs/CER_thresholds/en/index.html. [Acessed on jan/2011].
16. Hiligsmann M, Ethgen O, Bruyère O, Richy F, Gathon HJ, Reginster JY. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 2009; 12(5):687-96.
17. Borgström F, Ström O, Marin F, Kutahov A, Ljunggren O. Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis. J Med Econ 2010; 13(3):381-92.
18. Lundkvist J, Johnell O, Cooper C, Sykes D. Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. Osteoporos Int 2006; 17(2):201-11.
19. Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005; 9(22):1-160.
20. Rosner AJ, Grima DT, Torrance GW, Bradley C, Adachi JD, Sebaldt RJ et al. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 1998; 14(5):559-73.
21. Iglesias CP, Torgerson DJ, Bearne A, Bose U. The cost utility of bisphosphonate treatment in established osteoporosis. QJM 2002; 95(5):305-11.
22. Johnell O, Jönsson B, Jönsson L, Black D. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003; 21(5):305-14.
23. Brecht JG, Kruse HP, Felsenberg D, Möhrke W, Oestreich A, Huppertz E. Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int J Clin Pharmacol Res 2003; 23(4):93-105.
24. Borgström F, Carlsson A, Sintonen H, Boonen S, Haentjens P, Burge R et al. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 2006; 17(7):996-1007.
25. Goeree R, Blackhouse G, Adachi J. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada. Curr Med Res Opin 2006; 22(7): 1425-36.
26. Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 2006; 166(11):1209-17.
27. Ström O, Borgström F, Sen SS, Boonen S, Haentjens P, Johnell O et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007; 18(8):1047-61.
28. Earnashaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin 2007; 23(10):2517-29.
29. Tosteson AN, Burge RT, Marshall DA, Lindsay R. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am H Manag Care 2008; 14(9):605-15.
30. Wasserfallen JB, Krieg MA, Greiner RA, Lamy O. Cost-effectiveness and cost-utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective. J Med Econ 2008; 11(3):499-523.
31. Berto P, Maggi S, Noale M, Lopatriello S. Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. Aging Clin Exp Res 2010; 22(2):179-88.
32. Escolar CR, García MLF, Cebrián SR. Análisis coste-efectividad del alendronato frente a placebo en la prevención de fractura de cadera. Aten Primaria 1999; 24:390-6.
33. Silva LK. Avaliação tecnológica em saúde: densitometria óssea e terapêuticas alternativas na osteoporose pós-menopausa. Cad Saúde Pública 2003; 19(4):987-1003.
34. Kanis JA, Borgström F, Johnell O, Jonsson B. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 2004; 15(11):862-71.
35. Grima DT, Papaioannou A, Thompson MF, Pasquale MK, Adachi JD. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis. Osteoporos Int 2008; 19(5):687-97.
36. Araújo DV, Bahia LR, Souza CPR, Fernandes RA, Navarro J, Bueno RLP. Análise de custo-efetividade do ácido zolendrônico na prevenção da fratura osteoporótica proximal de fêmur no cenário do Sistema Suplementar de Saúde Brasileiro. Rev Bras Geriatr Gerontol 2008; 11(3):357-68.
37. Lekander I, Borgström F, Ström O, Zethraeus N, Kanis JA. Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK - results based on the Women's Health Initiative randomised controlled Trial. Bone 2008; 42(2):294-306.
38. Borgström F, Johnell O, Kanis JA, Oden A, Sykes D, Jönsson B. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 2004; 22(17):1153-65.
39. Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E. Healtheconomic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharmacol Res 2004; 24(1):1-10.
40. Borgström F, Jönsson B, Ström O, Kanis JA. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 2006; 17(12):1781-93.
41. Hiligsmann M, Bruyère O, Reginster JY. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Bone 2010; 46(2):440-6.
42. Hiligsmann M, Bruyère O, Reginster JY. Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int 2010; 21(1):157-65.
43. Willis MS. The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden. Int J Technol Assess Health Care 2002; 18(4):791-807.
44. Hiligsmann M, Reginster JY. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone 2010; 47(1):34-40.
45. Jönsson B, Ström O, Eisman JA, Papaioannou A, Siris ES, Tosteson A. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 2011; 22(3):967-82.
46. Hiligsmann M, Reginster JY. Cost-effectiveness of denosumab compared with oral bisphosphonates int the treatment of postmenopausal osteoporotic women in Belgium. Pharmacoeconomics 2011; 29(10):895-911.
47. Pinheiro MM, Camargos BM, Borba VZ, Lazaretti-Castro M. FRAXTM: construindo uma ideia para o Brasil. Arq Bras Endocrinol Metab 2009; 53(6):783-90.
48. Pinheiro MM, Reis Neto ET, Machado FS, Omura F, Szejnfeld J, Szejnfeld VL. Development and validation of a tool for identifying women with low bone mineral density and low-impact fractures: the São Paulo Osteoporosis Risk Index (SAPORI). Osteoporos Int 2012; 23(4):1371-9.
49. Fundació Institut Català de Farmacologia. Bifosfonatos: uma relación beneficio-riesgo dudosa. Butlletí groc 2009; 22(3):9-12.
50. Arantes HP, Silva AG, Lazaretti-Castro M. Bisphosphonates in the treatment of metabolic bone diseases. Arq Bras Endocrinol Metabol 2010; 54(2):206-12.
51. Passeri LA, Bértolo MB, Abuabara A. Osteonecrose dos maxilares associada ao uso de bisfosfonatos. Rev Bras Reumatol 2011; 51(4):401-7.
52. Kamath AF. Current controversies in bisphosphonate therapy. Orthopedics 2009; 32(7):473.
53. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Womens Health Initiative randomized controlled trial. JAMA 2002; 288(3):321-33.
54. Sacco SM, Ward WE. Revisiting estrogen: efficacy and safety for postmenopausal bone health. J Osteoporos 2010; 2010:708931.
55. O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. Ranelato de estroncio para la prevención y el tratamiento de la osteoporosis postmenopáusica. Cochrane Library 2008; Issue 3. Chichester, UK: John Wiley & Sons, Ltd.
56. Iqbal J, Sun L, Zaidi M. Denosumab for the treatment of osteoporosis. Curr Osteoporos Rep 2010; 8(4):163-7.
57. Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I et al. Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies. J Bone Miner Res 2010; 25(10):2256-65.
58. Kumar KD, Rema R, Roy MD. Medicamentos para o tratamento da osteoporose: revisão. Rev Bras Reumatol 2011; 51(4):372-82.
59. Instituto Brasileiro de Geografia e Estatística (IBGE). Tábuas completas de mortalidade. [Acessed on 29 Sep 2010]. Available from: http://www.ibge.gov.br/home/estatistica/populacao/tabuadevida/2008/mulhe res.pdf.